Skip to main content
Translational Oncology logoLink to Translational Oncology
. 2022 Feb 10;18:101353. doi: 10.1016/j.tranon.2022.101353

Corrigendum to “MK2206 enhances cisplatin-induced cytotoxicity and apoptosis in testicular cancer through Akt signaling pathway inhibition” [Transl Oncol. 2020 Jul;13(7):100769]

Dingqi Sun 1,3, Jinhua Wang 2, Hui Zhang 1,3, Shuai Liu 1,3, Peng Wei 3, Haoran Wang 3, Zhen Xu 3, Qiang Fu 1,3,, Keqin Zhang 1,3,
PMCID: PMC8844722  PMID: 35152083

The authors regret the Ki-67 immunostaining of MK2206 group (the third image) in Figure 5B was misapplied in the originally published version of this article [1]. It has been corrected and modified as follows. This correction does not affect results and scientific conclusions of the research.

Fig. 5.

Fig 5

(B) Histological examination of the effect of CDDP and MK2206 on a P19 tumor in vivo. At day 15, the mice were sacrificed and the tumors were dissected. The expression of Ki-67 was assessed by immunohistochemistry. The percentage of Ki-67-positive cells in each treatment group was compared (*P<0.05 vs. control; **P<0.05, CDDP+MK2206 vs. CDDP; CDDP+ MK2206 vs. MK2206).

The authors would like to apologize for any inconvenience caused.

Contributor Information

Qiang Fu, Email: qiangfu68@163.com.

Keqin Zhang, Email: 270638805@qq.com.

Reference

  • 1.Sun Dingqi, Wang Jinhua, Zhang Hui, Liu Shuai, Wei Peng, Wang Haoran, Xu Zhen, Fu Qiang. Keqin Zhang. MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition. Transl Oncol. 2020 Jul;13(7) doi: 10.1016/j.tranon.2020.100769. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Translational Oncology are provided here courtesy of Neoplasia Press

RESOURCES